Jung Haebeen, Paust Silke
The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
Front Immunol. 2024 Jul 16;15:1443366. doi: 10.3389/fimmu.2024.1443366. eCollection 2024.
The tumor microenvironment (TME) is a complex interconnected network of immune cells, fibroblasts, blood vessels, and extracellular matrix surrounding the tumor. Because of its immunosuppressive nature, the TME can pose a challenge for cancer immunotherapies targeting solid tumors. Chemokines have emerged as a crucial element in enhancing the efficacy of cancer immunotherapy, playing a direct role in immune cell signaling within the TME and facilitating immune cell migration towards cancer cells. However, chemokine ligands and their receptors exhibit context-dependent diversity, necessitating evaluation of their tumor-promoting or inhibitory effects based on tumor type and immune cell characteristics. This review explores the role of chemokines in tumor immunity and metastasis in the context of the TME. We also discuss current chemokine-related advances in cancer immunotherapy research, with a particular focus on lung cancer, a common cancer with a low survival rate and limited immunotherapy options.
肿瘤微环境(TME)是围绕肿瘤的免疫细胞、成纤维细胞、血管和细胞外基质组成的复杂相互连接网络。由于其免疫抑制特性,TME可能对针对实体瘤的癌症免疫疗法构成挑战。趋化因子已成为增强癌症免疫疗法疗效的关键因素,在TME内的免疫细胞信号传导中发挥直接作用,并促进免疫细胞向癌细胞迁移。然而,趋化因子配体及其受体表现出依赖于背景的多样性,需要根据肿瘤类型和免疫细胞特征评估它们的促肿瘤或抑制作用。本综述探讨了趋化因子在TME背景下在肿瘤免疫和转移中的作用。我们还讨论了癌症免疫疗法研究中当前与趋化因子相关的进展,特别关注肺癌,这是一种生存率低且免疫疗法选择有限的常见癌症。